Page 87 - Read Online

Table 5: EFS and OS of 418 DLBCNHL patients
Group n EFS OS
Median 2-year rate 5-year rate P Median 2-year rate 5-year rate P
All 418 22.0 47.8 30.4 28.6 53.3 37.9
First line chemotherapy
CHOP 351 32.2 55.3 36.0 49.5 61.8 45.0
CVP 67 3.5 8.1 0 < 0.001 3.7 9.7 0 < 0.001
Age (years)
< 60 297 39.4 59.6 39.9 57.4 67.0 49.6
≥ 60 121 6.3 18.2 5.7 < 0.001 6.0 19.0 6.3 < 0.001
Gender
Male 212 17.8 43.6 25.0 25.0 50.0 35.6
Female 206 26.8 52.2 35.9 0.032 43.0 56.7 40.3 0.188
Comorbidities
No 293 35.2 56.0 36.2 53.7 63.3 46.4
Yes 125 7.2 28.4 16.4 < 0.001 8.0 28.8 16.7 < 0.001
Bulky disease
Yes 46 13.9 34.8 24.6 17.0 43.5 31.2
No 372 23.9 49.5 31.1 0.178 31.1 54.6 38.8 0.407
B symptoms
A 218 28.8 54.7 36.4 46.2 60.0 42.8
B 200 16.0 40.2 32.6 0.002 18.0 45.8 32.6 0.003
PS
0-1 242 41.2 59.7 38.6 55.9 67.0 48.8
2-4 176 9.7 31.2 18.9 < 0.001 10.6 34.2 22.7 < 0.001
Extra-nodal
No 276 22.9 48.8 29.7 31.1 55.2 38.4
Yes 142 18.0 45.8 31.8 0.738 21.8 49.5 37.1 0.376
Stage
1.0 84 76.7 63.0 52.2 NR 68.1 5.6
2.0 148 20.6 45.3 29.2 28.0 52.4 36.8
3.0 142 19.1 44.4 21.3 25.6 50.3 32.8
4.0 44 6.9 39.5 19.1 < 0.001 8.8 41.9 21.9 < 0.001
Stage-group
1-2 232 26.0 51.6 37.4 44.2 57.3 43.4
3-4 186 16.3 43.2 20.7 0.001 21.3 48.3 30.7 0.006
IPI-group
Low 88 NR 72.0 57.6 NR 79.1 65.4
Low intermediate 165 28.9 54.1 31.3 45.6 62.3 42.2
High intermediate 104 14.1 39.3 21.3 16.3 42.5 27.2
High 61 4.6 9.2 0 < 0.001 4.6 10.7 0 < 0.001
aaIPI
0-1 107 52.0 62.4 84.2 NR 68.3 54.7
2-3 311 17.8 42.8 24.1 < 0.001 20.5 46.5 32.1 < 0.001
Radiotherapy
No 338 17.2 43.5 26.6 20.0 47.9 32.9
Yes 80 50.7 66.1 46.0 < 0.001 72.5 77.5 58.8 < 0.001
EFS: Event-free survival; OS: Overall survival; DLBCNHL: Diffuse large B-cell non-Hodgkin’s lymphoma; CHOP: Cyclophosphamide,
doxorubicin, vincristine, and prednisone; CVP: Cyclophosphamide, vincristine, and prednisone; PS: Performance status; IPI: International
prognostic index; aaIPI: Age adjusted international prognostic index; NR: Not reached

combination of cyclophosphamide, vincristine, and 11-fold higher relative risk of death. CHOP-produced
prednisolone (from 29.9% to 69.9%) in DLBCNHL CR rates is comparable to those reported by Khaled
[29]
[30]
treated solely by chemotherapy. Achieving CR is et al., Burton et al., Hallack Neto et al. [Table 7].
[28]
[27]
crucial for long-term survival and cure. Our current However, a large Egyptian study by Abdelhamid et al.
[6]
study clearly shows that patients are failing to achieve reported a 10% higher CR rate. This latter study only
CR only had a median OS of 4.4 months compared to included younger patients with a maximum age of 60,
76.8 months in those who achieved CR with almost better PS, and lower aaIPI scores. In contrast, our current
80 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦